The stock's fall snapped a four-day winning streak.

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

This week's dividend activity included increased payouts from General Mills (GIS) and Worthington Enterprises (WOR) as well ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Macquarie Asset Management, an investment management company, released its “Macquarie Large Cap Growth Fund” first quarter ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly and Company (NYSE:LLY) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the most frequently ...

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...